Advertisement

Organisation › Details
Qiagen Marseille S.A.
Ipsogen, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path. With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow up of thousands of patients with leukemia, Ipsogen is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information. Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, Ipsogen intends to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society. The company is headquartered in Marseilles, France, and has a subsidiary in the US. *
![]() |
Start | 2013-01-01 renamed |
Group | Qiagen (Group) | |
Predecessor | Ipsogen S.A. | |
![]() |
Industry | molecular diagnostics |
Industry 2 | diagnostic test, cancer | |
![]() |
Region | Marseille |
Country | France | |
Street | 163 avenue de Luminy Luminy Biotech Entreprises, Case 923 | |
City | 13288 Marseille Cedex 09 | |
Tel | +33-4-9129-3090 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2008-04-30) |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Qiagen (Group)
- [1] Qiagen N.V.. (9/18/24). "Press Release: Qiagen Expands QIAcuity Digital PCR Offering with over New 100 Assays via GeneGlobe Platform". Venlo....
- [2] Qiagen N.V.. (9/12/24). "Press Release: Qiagen and Bio-Manguinhos/Fiocruz Collaborate to Enhance Malaria and Dengue Detection in Brazil’s National Screening Programs". Venlo & Rio de Janeiro....
- [3] Qiagen N.V.. (9/4/24). "Press Release: Qiagen and Lilly Collaborate to Support Development of a QIAstat-Dx IVD Panel that Identifies Patients at Risk for Developing Alzheimer’s disease". Venlo....
- [4] Qiagen N.V.. (9/3/24). "Press Release: Qiagen N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds [not for US, CA, AU, JP, ZA, et al.]". Venlo....
- [5] Qiagen N.V.. (8/28/24). "Press Release: Qiagen Expands QIAstat-Dx into Precision Medicine through Partnership for Companion Diagnostics in Chronic Diseases". Venlo....
- [6] Evotec SE. (6/3/24). "Press Release: Evotec and Qiagen Enter Software Collaboration for Enhanced Multi-omics Data Insights". Hamburg & Venlo....
- [7] Qiagen N.V.. (1/4/24). "Press Release: Qiagen to Accelerate Investments into Qiagen Digital Insights Bioinformatics Business". Venlo....
- [8] Qiagen N.V.. (1/3/24). "Press Release: Qiagen Expands Business in Middle East with New Regional Headquarters and Major Projects". Venlo, Muscat & Ryadh....
- [9] Qiagen N.V.. (9/25/23). "Press Release: Qiagen Enhances QIAwave Portfolio with New Eco-friendlier Nucleic Acid Extraction Kits". Venlo....
- [10] Qiagen N.V.. (9/11/23). "Press Release: Qiagen Launches API to Streamline Access to World-leading Biomedical Data for AI Integration". Venlo & Redwood City, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top